ClinicalTrials.gg
CompletedNCT06042049JUBILUSUpdated Apr 16, 2026Results posted

A Study to Assess Safety, Pharmacokinetics Anti-Drug Antibody and Anti-RSV Antibody After 2 Doses of Nirsevimab

A Phase 3 interventional study of Nirsevimab in Respiratory Syncytial Virus Infections, sponsored by AstraZeneca. Completed at 9 sites in Japan. Open to participants aged 0 Years to 1 Year. Per ClinicalTrials.gov, last updated 2026-04-16.

Sponsored by AstraZeneca · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
33
Allocation
Not applicable
Ages
0 Years to 1 Year
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Respiratory Syncytial Virus Infections by AstraZeneca — none open to participants now, none under way, none of them phase 3. Respiratory Syncytial Virus Infections · AstraZeneca.

Enrollment
10th of 12
33 · median 239
Started
2023
the only one that year
Phase 3
3 of 14
none open now
Registered
14th of 14
by date

Among the 14 studies in Respiratory Syncytial Virus Infections by AstraZeneca, this one is the 10th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2023, is one of 3 in phase 3, and was the 14th registered.

Respiratory Syncytial Virus Infections

306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.

Browse Respiratory Syncytial Virus Infections studies →

Open to participants now

None of the 14 studies in Respiratory Syncytial Virus Infections by AstraZeneca is open now. The open studies under Respiratory Syncytial Virus Infections, anywhere →

Who these studies take

Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.

This study: 0 Years to 1 Year · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies in Respiratory Syncytial Virus Infections by AstraZeneca as a file.
02

Study summary

The purpose of this study is to measure the safety, PK, occurrence of ADA to nirsevimab, and anti-RSV neutralizing Ab in Japanese children with certain health conditions or pre-term infants aged ≤12 months.

Study details include

  • The study duration is approximately 21 months with a 2-month enrollment period.
  • Study intervention is 2 doses administered 5- 6 months apart.
  • The study has 5 or 6 site visits and several telephone contacts with a 2 or 4 week interval.
03

Conditions studied

  • Respiratory Syncytial Virus Infections
04

Who can participate

Ages eligible
0 Years to 1 Year
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written and any locally required authorization obtained from the participant's parent(s)/legally authorized representative(s) before performing any protocol-related procedures, including screening evaluations
  2. Japanese infants of ≤12 months of age eligible to receive palivizumab in accordance with national or local guidelines and those who must meet at least one of the following conditions at the time of informed consent.

    1. Immunodeficiency
    2. Chronic Lung Disease
    3. Congenital Heart Disease
    4. Down syndrome
    5. Born pre-term ≤28 wks Gestation age and aged ≤12 months, or born pre-term >28 wks and ≤35 wks Gestation age and aged ≤6 months
  3. The participant's parent(s)/legally authorized representative(s) can understand and comply with the requirements of the protocol including follow-up visits as judged by the investigator.
  4. The participant is available to complete the follow-up period for approximately 19 months, which will be approximately 1 year after receipt of 2nd dose of nirsevimab

Exclusion criteria

Exclusion Criteria:

  1. Requirement for mechanical ventilation, extracorporeal membrane oxygenation, continuous positive airway pressure (CPAP), or other mechanical respiratory or cardiac support at the time of enrollment
  2. A current, active RSV infection at the time of screening and product administration
  3. Any fever (≥100.4°F [≥38.0°C], regardless of route) or acute illness at the time of prior to investigational product administration
  4. Any serious concurrent medical condition (except those resulting in an immune deficiency condition), including:

    1. Known renal impairment
    2. Known hepatic dysfunction including known or suspected active or chronic hepatitis infection
    3. Any seizure disorder or evolving or unstable neurological condition
  5. Anticipated cardiac surgery within 5-6 months after enrollment
  6. Prior history of a suspected or actual acute life-threatening event
  7. Receipt or intended use of palivizumab in the current enrollment season
  8. Any known allergy or history of allergic reaction to any component of nirsevimab
  9. Any known allergy or history of allergic reaction to immunoglobulin products, blood products, or other foreign proteins
  10. Concurrent enrollment in another interventional study, or prior receipt of any investigational agent
  11. Anticipated survival of less than 1 year at the time of
  12. Any condition that, in the opinion of the investigator, would interfere with the evaluation of the investigational product or interpretation of study results
  13. Children of employees of the Sponsor, clinical study site, or any other individuals involved with the conduct of the study, or immediate family members of such individuals
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    MEDI8897

    Anti-RSV monoclonal antibody

    Drug: Nirsevimab

Interventions

  • Participants in the first year of life will receive the 1st dose of nirsevimab as a single, fixed intramuscular (IM) dose of 50 mg if body weight is \<5 kg or 100 mg if body weight is ≥5 kg. A 2nd fixed IM dose of 50 mg if body weight is \<5 kg or 100 mg if body weight is ≥5 kg will be administered 5 to 6 months following the 1st dose.

    Also known as: MEDI8897

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs), Adverse Events of Special Interest (AESIs), and New-onset Chronic Diseases (NOCDs)

    An AE was development of any untoward medical occurrence in a participant or clinical study participant administered medicinal product and which did not necessarily have causal relationship with this treatment. TEAEs were AEs whose onset occurred after receiving nirsevimab through 360 days post second dose. An SAE was any AE that resulted in death, was immediately life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly or birth defect or was an important medical event that might jeopardize the participant or may require medical treatment to prevent 1 of the outcomes listed above. AESIs were based on assessment by investigators following the administration of nirsevimab. An NOCD was a newly diagnosed medical condition of chronic, ongoing nature post administration of study drug.

    Time frame: From the first dose administration (Day 1) through 360 days post 2nd dose, study Day 511

Secondary outcomes

  1. Serum Concentrations of Nirsevimab

    Serum samples were collected at specified timepoints to evaluate concentrations of nirsevimab at selected time points.

    Time frame: Pre-dose Day 1, pre-dose Day 151, Day 181 post first-dose, Day 301 post first-dose, and Day 511 post first-dose

  2. Number of Participants With Anti-drug Antibody (ADA) Response to Nirsevimab

    Blood samples were analyzed for the presence of ADAs for nirsevimab using an appropriately validated bioanalytical method.

    Time frame: Pre-dose Day 1, pre-dose Day 151, Day 181 post first-dose, Day 301 post first-dose, and Day 511 post first-dose

  3. Serum Anti-respiratory Syncytial Virus (RSV) Neutralizing Antibody (nAb) Levels

    Blood samples were collected for the determination anti-RSV nAb in serum using an appropriately validated bioanalytical method.

    Time frame: Pre-dose Day 1, pre-dose Day 151, Day 181 post first-dose, Day 301 post first-dose, and Day 511 post first-dose

07

Results

Posted Apr 16, 2026

Participant flow

This Phase III, single-arm, open-label study was conducted at 9 investigational sites in Japan in infants (\< or equal to 12 months of age at enrolment) with congenital heart disease, chronic lung disease, immunocompromise, down syndrome, or born pre-term.

Participant flow — Overall Study
MilestoneNirsevimab 50 mg/100 mg
Started33
Received study dose 133
Received study dose 232
Completed33
Not completed0

Outcome measures

SecondarySerum Concentrations of Nirsevimab

Serum samples were collected at specified timepoints to evaluate concentrations of nirsevimab at selected time points.

Time frame:
Pre-dose Day 1, pre-dose Day 151, Day 181 post first-dose, Day 301 post first-dose, and Day 511 post first-dose
Reported as:
Geometric mean · microgram/milliliter (mcg/mL)
Serum Concentrations of Nirsevimab
microgram/milliliter (mcg/mL)Nirsevimab 50 mg/100 mg
Pre-dose Day 10 ± 0
Pre-dose Day 15124.362 ± 24.639
Day 181129.554 ± 19.090
Day 30136.239 ± 48.154
Day 5113.234 ± 111.784
SecondaryNumber of Participants With Anti-drug Antibody (ADA) Response to Nirsevimab

Blood samples were analyzed for the presence of ADAs for nirsevimab using an appropriately validated bioanalytical method.

Time frame:
Pre-dose Day 1, pre-dose Day 151, Day 181 post first-dose, Day 301 post first-dose, and Day 511 post first-dose
Reported as:
Count of participants · Participants
Number of Participants With Anti-drug Antibody (ADA) Response to Nirsevimab
ParticipantsNirsevimab 50 mg/100 mg
Pre-dose Day 10
Pre-dose Day 1510
Day 1810
Day 3010
Day 5114
SecondarySerum Anti-respiratory Syncytial Virus (RSV) Neutralizing Antibody (nAb) Levels

Blood samples were collected for the determination anti-RSV nAb in serum using an appropriately validated bioanalytical method.

Time frame:
Pre-dose Day 1, pre-dose Day 151, Day 181 post first-dose, Day 301 post first-dose, and Day 511 post first-dose
Reported as:
Geometric mean · international units/mL
Serum Anti-respiratory Syncytial Virus (RSV) Neutralizing Antibody (nAb) Levels
international units/mLNirsevimab 50 mg/100 mg
Pre-dose Day 1254.6 ± 79.2
Pre-dose Day 1518127.4 ± 18.8
Day 18128552.2 ± 9.5
Day 30111241.0 ± 24.8
Day 5111302.1 ± 58.1
PrimaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs), Adverse Events of Special Interest (AESIs), and New-onset Chronic Diseases (NOCDs)

An AE was development of any untoward medical occurrence in a participant or clinical study participant administered medicinal product and which did not necessarily have causal relationship with this treatment. TEAEs were AEs whose onset occurred after receiving nirsevimab through 360 days post second dose. An SAE was any AE that resulted in death, was immediately life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly or birth defect or was an important medical event that might jeopardize the participant or may require medical treatment to prevent 1 of the outcomes listed above. AESIs were based on assessment by investigators following the administration of nirsevimab. An NOCD was a newly diagnosed medical condition of chronic, ongoing nature post administration of study drug.

Time frame:
From the first dose administration (Day 1) through 360 days post 2nd dose, study Day 511
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs), Adverse Events of Special Interest (AESIs), and New-onset Chronic Diseases (NOCDs)
ParticipantsNirsevimab 50 mg/100 mg
TEAE32
TESAE8
AESI0
NOCD1

Adverse events

Collected over From 1st dose through 360 days after 2nd dose. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nirsevimab0/32 (0%)8/32 (25%)32/32 (100%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventNirsevimab
Infantile spasmsNervous system disorders1/32
ApnoeaRespiratory, thoracic and mediastinal disorders1/32
AsthmaRespiratory, thoracic and mediastinal disorders1/32
BronchitisInfections and infestations1/32
Bronchitis viralInfections and infestations1/32
Metapneumovirus pneumoniaInfections and infestations1/32
Pneumonia bacterialInfections and infestations1/32
Viral sepsisInfections and infestations1/32
Thermal burnInjury, poisoning and procedural complications1/32
Gastroenteritis adenovirusInfections and infestations1/32
Most frequent other events
Showing 10 of 95
Most frequent other events
EventNirsevimab
Upper respiratory tract infectionInfections and infestations25/32
PyrexiaGeneral disorders14/32
Hand-foot-and-mouth diseaseInfections and infestations12/32
Viral upper respiratory tract infectionInfections and infestations10/32
DiarrhoeaGastrointestinal disorders9/32
NasopharyngitisInfections and infestations9/32
Dermatitis diaperSkin and subcutaneous tissue disorders8/32
EczemaSkin and subcutaneous tissue disorders8/32
GastroenteritisInfections and infestations7/32
Immunisation reactionInjury, poisoning and procedural complications6/32

Baseline characteristics

Age, Continuous
Age, Continuous(months)Nirsevimab 50 mg/100 mg
As-Treated Set 12.32 ± 2.39
As-Treated Set 22.32 ± 2.43
Sex: Female, Male
Sex: Female, Male(Participants)Nirsevimab 50 mg/100 mg
As-Treated Set 1 — Female15
As-Treated Set 1 — Male18
As-Treated Set 2 — Female14
As-Treated Set 2 — Male18
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Nirsevimab 50 mg/100 mg
As-Treated Set 1 — Asian33
As-Treated Set 2 — Asian32
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Nirsevimab 50 mg/100 mg
As-Treated Set 1 — Hispanic or Latino0
As-Treated Set 1 — Not Hispanic or Latino33
As-Treated Set 1 — Unknown or Not Reported0
As-Treated Set 2 — Hispanic or Latino0
As-Treated Set 2 — Not Hispanic or Latino32
As-Treated Set 2 — Unknown or Not Reported0
08

Study locations

9 sites
  • Research Site
    Bunkyō City, 113-8519, Japan
  • Research Site
    Fuchu-shi, 183-8561, Japan
  • Research Site
    Fukuoka, 813-0017, Japan
  • Research Site
    Kitakyusyu-shi, 806-8501, Japan
  • Research Site
    Kōtoku, 135-8577, Japan
  • Research Site
    Kurume-shi, 830-0011, Japan
  • Research Site
    Nagasaki, 852-8501, Japan
  • Research Site
    Saitama-shi, 336-8522, Japan
  • Research Site
    Yokohama, 232 8555, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2023 to primary completion in Jul 2025, 23 months.

Results were first posted in Apr 2026, 8 months after primary completion.

Of 27 industry-sponsored phase 3 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 19. This study's 23 months is above that.

Counting every sponsor, half of 32 studies reached it within 8 months; a quarter within 6 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2023
First posted
Sep 18, 2023
StartActual
Jul 27, 2023
Primary completionActual
Jul 24, 2025
CompletionActual
Jul 24, 2025
Results first posted
Apr 16, 2026
Last update
Apr 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06042049
Lead sponsor
AstraZeneca
Collaborators
IQVIA Pty Ltd
Responsible party
Sponsor
First posted
Sep 18, 2023
Start date
Jul 27, 2023
Primary completion
Jul 24, 2025
Completion
Jul 24, 2025
Results posted
Apr 16, 2026
Last update
Apr 16, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nirsevimab

Start the discussion